Table 1. Patients characteristics at baseline.
| PCH (N=50) | PEH(N=50) | P value | |
|---|---|---|---|
| Median age, yr(range) | 48(29-65) | 47.5(30-63) | 0.225 |
| Menopausal status | |||
| Premenopausal | 30 | 31 | 0.544 |
| Postmenopausal | 20 | 16 | |
| Clinical tumor stage | |||
| cT1 | 1 | 1 | 0.970 |
| cT2 | 32 | 34 | |
| cT3 | 13 | 12 | |
| cT4 | 4 | 3 | |
| Clinical lymph node stage | |||
| cN0 | 7 | 8 | 0.511 |
| cN1 | 21 | 27 | |
| cN2 | 15 | 9 | |
| cN3 | 6 | 6 | |
| Estrogen receptor | |||
| Positive | 26 | 19 | 0.183 |
| Negative | 23 | 29 | |
| Progesterone receptor | |||
| Positive | 20 | 16 | 0.446 |
| Negative | 29 | 32 | |
| Ki67 index | |||
| ≥14% | 40 | 39 | 0.592 |
| <14% | 6 | 8 | |
| LVEF | |||
| Median, range | 67(58-79) | 65(56.5-83) | 0.443 |
| Chemotherapy cycle | |||
| 4 cycles | 23 | 25 | 0.382 |
| Over 4 cycles | 24 | 18 | |
| FCGR2A | 0.278 | ||
| AA | 22 | 14 | |
| AG/GG | 20 | 21 | |
| FCGR3A | 0.298 | ||
| TT | 19 | 20 | |
| TG/GG | 23 | 15 | |
| PIK3CA status | 0.765 | ||
| Wide type | 25 | 22 | |
| mutated | 17 | 13 | |
| TP53 mutation | 0.868 | ||
| Wide type | 22 | 19 | |
| Mutated | 20 | 16 | |
| PTEN | 0.693 | ||
| Loss | 11 | 9 | |
| Normal | 35 | 35 |